Medicamen Biotech Limited
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Medicamen Biotech Limited generated cash of -$67,438,000, which is less than the previous year. Cash used in financing activities reached the amount of $63,135,000 last year. Net change in cash is therefore -$59,932,000.
Cash Flow
| 2012 | -34.89M | -14.89M | 30.77M |
|---|---|---|---|
| 2016 | 62.05M | -5.35M | -47.32M |
| 2018 | -54.53M | -79.90M | 331.40M |
| 2020 | 128.01M | -372.91M | 190.62M |
| 2021 | 127.71M | -178.12M | 58.38M |
| 2023 | -62.92M | -58.80M | 291.27M |
| 2024 | -67.43M | -55.62M | 63.13M |
MEDICAMEQ.NS Cash Flow Statement (2012 – 2023)
| 2023 | 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 207.78M | 38.24M | 30.92M | 85.19M | 29.68M | 22.93M | 48.08M |
Operating activities | |||||||
Net income | 109.31M | 147.28M | 121.29M | 132.91M | 101.12M | 4.80M | -8.24M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 70.93M | 63.66M | 25.19M | 24.99M | 20.57M | 18.96M | 15.02M |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 99.98M | -20.34M | -25.89M | -65.87M | -127.37M | 104.20M | 0 |
Inventories | -143.17M | -180.47M | 117.53M | -16.97M | -4.44M | 23.25M | -1.73M |
Accounts payable | -21.67M | 42.85M | -51.69M | 68.11M | -5.06M | -77.67M | 0 |
Cash generated by operating activities | -67.43M | -62.92M | 127.71M | 128.01M | -54.53M | 62.05M | -34.89M |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -200K |
Investments In Property Plant And Equipment | -62.87M | -66.01M | -179.65M | -376.10M | -81.85M | -6.73M | -16.17M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -55.62M | -58.80M | -178.12M | -372.91M | -79.90M | -5.35M | -14.89M |
Financing activities | |||||||
Common Stock Issued | 18.96M | 334.11M | 1.54M | 250.55M | 390.46M | 2.43M | 969.1K |
Payments for dividends | -12.65M | -12.65M | -6.10M | -14.70M | -11.07M | 0 | 0 |
Repurchases of common stock | 0 | 0 | -75.13M | 0 | 0 | 0 | 0 |
Repayments of term debt | 66.34M | -1.65M | -73.59M | 23.37M | -21.65M | -18.74M | -6.86M |
Cash used in financing activities | 63.13M | 291.27M | 58.38M | 190.62M | 331.40M | -47.32M | 30.77M |
Net Change In Cash | -59.93M | 169.54M | 7.97M | -54.26M | 196.95M | 9.37M | -19.01M |
Cash at end of period | 147.85M | 207.78M | 38.90M | 30.92M | 226.64M | 32.31M | 29.06M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |